| Recruiting | Donidalorsen Treatment in Children With Hereditary Angioedema NCT07298447 | Ionis Pharmaceuticals, Inc. | Phase 3 |
| Not Yet Recruiting | A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema NCT07293364 | Takeda | N/A |
| Not Yet Recruiting | A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea NCT07445087 | Takeda | — |
| Not Yet Recruiting | A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt NCT07218393 | Takeda | — |
| Not Yet Recruiting | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia NCT07263685 | Takeda | — |
| Not Yet Recruiting | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) NCT07428499 | ADARx Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries NCT07251933 | Takeda | — |
| Enrolling By Invitation | A Long-Term Study of Navenibart in Participants With Hereditary Angioedema NCT07204938 | Astria Therapeutics, Inc. | Phase 3 |
| Recruiting | A Study of Navenibart in Participants With Hereditary Angioedema NCT06842823 | Astria Therapeutics, Inc. | Phase 3 |
| Recruiting | Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients NCT07046806 | Institute for Asthma and Allergy | Phase 1 / Phase 2 |
| Not Yet Recruiting | Suicide Ideation in Hereditary Angioedema NCT06811467 | Ivan Cherrez Ojeda | — |
| Recruiting | HAE Burden and Crisis Management NCT06806618 | University Hospital, Grenoble | — |
| Active Not Recruiting | A Phase 2 in Adult Subjects With Hereditary Angioedema NCT06846398 | Shanghai Argo Biopharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema A NCT06679881 | Pharvaris Netherlands B.V. | Phase 3 |
| Active Not Recruiting | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents NCT06669754 | Pharvaris Netherlands B.V. | Phase 3 |
| Completed | A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People NCT06587464 | Takeda | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema NCT07290855 | Nang Kuang Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China NCT06346899 | Takeda | — |
| Active Not Recruiting | A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) NCT05469789 | Takeda | — |
| Completed | A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With No NCT05578417 | Takeda | — |
| Completed | CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema NCT05819775 | CSL Behring | Phase 3 |
| Enrolling By Invitation | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angio NCT05396105 | Pharvaris Netherlands B.V. | Phase 2 / Phase 3 |
| Completed | A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home NCT05489640 | Takeda | — |
| Completed | A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema NCT05509569 | Takeda | — |
| Completed | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) NCT05460325 | Takeda | Phase 3 |
| Active Not Recruiting | A Survey of Lanadelumab in Participants With Hereditary Angioedema NCT05397431 | Takeda | — |
| Completed | A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland NCT05147181 | Takeda | — |
| Completed | A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long NCT04861090 | Takeda | — |
| Completed | Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) NCT04180163 | Shire | Phase 3 |
| Completed | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II NCT04130191 | Shire | — |
| Completed | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America NCT03845400 | Shire | — |
| Completed | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in NCT03873116 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | FIRAZYR General Drug Use-Results Survey (Japan) NCT04057131 | Shire | — |
| Completed | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema NCT03240133 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks i NCT02865720 | Shire | Phase 3 |
| Completed | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema NCT02870972 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With T NCT02741596 | Shire | Phase 3 |
| Completed | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II H NCT02586805 | Shire | Phase 3 |
| Completed | Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibi NCT02663687 | Shire | Phase 1 |
| Completed | Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for th NCT02584959 | Shire | Phase 3 |
| Completed | A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants NCT03888755 | Shire | Phase 3 |
| Completed | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 i NCT02093923 | Shire | Phase 1 |
| Completed | Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditar NCT02052141 | Shire | Phase 3 |
| Completed | Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous NCT02045264 | Shire | Phase 1 |
| Completed | A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects NCT01923207 | Shire | Phase 1 |
| Completed | Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks NCT01756157 | Shire | Phase 2 |
| Withdrawn | Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema NCT01253382 | Shire | Phase 2 / Phase 3 |
| Completed | A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema NCT01541423 | Shire | — |
| Completed | A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angi NCT01386658 | Shire | Phase 3 |
| Completed | CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 NCT01095510 | Shire | Phase 2 |
| Completed | Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioede NCT01059526 | Shire | — |
| Completed | Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) NCT01034969 | Shire | — |
| Completed | Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) NCT00457015 | Shire | Phase 3 |
| Completed | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema ( NCT00456508 | Shire | Phase 3 |
| Completed | Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) NCT00262080 | Shire | Phase 3 |
| Completed | EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema NCT01826916 | Shire | Phase 2 |
| Available | Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Compl NCT07159464 | CSL Behring | — |
| No Longer Available | Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-h NCT04583007 | Shire | — |